AGLE Quote, Trading Chart, Aeglea BioTherapeutics Inc.
home / stock / agle / agle quote
$6.32 Last:
-0.78% Change Percent:
$6.31 Open:
$6.32 Previous Close:
$6.37 High:
$6.15 Low:
111,193 Volume:
06/22/2021 04:42:18 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
AGLE Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-22 | 6.31 | 6.32 | 6.37 | 6.15 | 111,193 |
| 2021-06-21 | 6.48 | 6.37 | 6.51 | 6.3 | 110,482 |
| 2021-06-18 | 6.49 | 6.44 | 6.53 | 6.4 | 236,324 |
| 2021-06-17 | 6.53 | 6.53 | 6.59 | 6.435 | 117,767 |
| 2021-06-16 | 6.53 | 6.56 | 6.61 | 6.46 | 152,079 |
| 2021-06-15 | 6.66 | 6.56 | 6.66 | 6.5 | 103,985 |
| 2021-06-14 | 6.66 | 6.59 | 6.68 | 6.5 | 88,993 |
| 2021-06-11 | 6.57 | 6.6 | 6.6979 | 6.52 | 110,176 |
| 2021-06-10 | 6.69 | 6.54 | 6.79 | 6.48 | 418,053 |
| 2021-06-09 | 6.8 | 6.65 | 7.06 | 6.63 | 165,228 |
| 2021-06-08 | 6.75 | 6.8 | 6.93 | 6.68 | 282,536 |
| 2021-06-07 | 6.62 | 6.7 | 6.84 | 6.62 | 339,442 |
| 2021-06-04 | 6.71 | 6.57 | 6.71 | 6.5 | 165,508 |
| 2021-06-03 | 6.58 | 6.7 | 6.75 | 6.4441 | 123,725 |
| 2021-06-02 | 6.95 | 6.62 | 6.95 | 6.46 | 289,031 |
| 2021-06-01 | 6.55 | 6.93 | 6.95 | 6.36 | 183,117 |
| 2021-05-31 | 6.8 | 6.61 | 7.02 | 6.57 | 304,365 |
| 2021-05-28 | 6.8 | 6.61 | 7.02 | 6.57 | 301,952 |
| 2021-05-27 | 6.86 | 6.76 | 6.95 | 6.61 | 530,109 |
| 2021-05-26 | 6.72 | 6.77 | 6.84 | 6.62 | 65,399 |
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors PR Newswire AUSTIN, Texas , June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeuti...
-
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights Completed Patient Randomization for Phase 3 PEACE Clinical Trial; Topline Data Expected in Q4 Entered into Ex-U.S. Commercialization Agreement for Pegzilarginase with Upfront and Mil...
-
Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency Includes Sponsored Diagnostic Testing and Services for Patients with Suspected Arginase 1 Deficiency PR Newswire A...